Manishkumar Patel

Senior Researcher

Icahn School of Medicine at Mount Sinai
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (24)

Supplemental Figure 2. Cellular marker dynamics in Hodgkin lymphoma during checkpoint blockade treatment. A. Heatmap showing markers and cell types identified through CyTOF (cytometry using time of flight) that significantly change over time. The color indicates the standardized Log2FC in protein expression (Z-Score), and the size of the circles indicate the percent of cells expressing the marker. A dendrogram of the markers sorted hierarchically is shown on the right side. B. Line plots highlight the temporal changes for each of the markers shown in A. The color separates the values per treatment. C. Heatmap showing markers and cell types significantly associated with R (Responder) and NR (Not responder). D. Regression lines for examples of markers and cell types shown in C, separating response (R) and non-response (NR).

Year:

2025

Supplemental Figure 3. Graphical abstract. Top boxes show a simplified trial design including 3 treatments composed by the combination of BV with I, N and I+N. We investigated the differences between responders and non-responders using standardized assays through the CIMAC’s network (ELISA, Olink, CYTOF and TCRseq). Bottom boxes summarize the main findings associated with specific treatments and treatment associated response or resistance.

Year:

2025

Cancer antigen detection and T-cell clonal dynamics associated with treatment and response. A, Heatmap showing cancer antigen detection by ELISA for all samples. The color represents the log 10 scale antibody titers. Positive detection is considered above levels of 2 (pink), whereas negative detection is represented by the color black. The top rows of the figure show the treatment group, best overall response, and time. The figure is separated into nonresponders (left) and responders (right). Each column box is hierarchically clustered for simplicity. B, Pie charts showing the association of NY-ESO-1 presence (left column) and nondetection (middle column). Boxplots (right column) show all titer levels for nonresponders and responders. C, Boxplots showing the standardized absolute clonal diversity index calculated using Immunarch R package. The clonal diversity changes are shown over four time points (Baseline, C2D1, Restaging, and off-study) per treatment arm. The P value from the Wilcoxon rank test is shown on top of the boxes. The y -axis is identical for all three treatment arms. There was no statistical difference between the treatments due to the observed large variances (patient heterogeneity). D, Boxplots showing an increase in clonal overlap over time for all three treatments. P values were estimated using the Wilcoxon rank test. E, Clonal expansion was stratified into unique and expanded clones (black and orange, respectively). The stacked barplot shows the average percent of each clonal expansion class over time and per treatment arm. There were no statistical differences identified between treatment arms. F, Boxplots showing the percent abundance of only expanded clones shown for responders and nonresponders over time. There were no significant differences between these two groups except for C2D1 using the Wilcoxon rank test. G, Clonal diversity boxplots comparing responders and nonresponders. Overall, responders had a higher diversity, yet it did not reach statistical significance.

Year:

2025

Cellular dynamics in HL during checkpoint blockade treatment. A, Cell type composition of major cell groups (myeloid and lymphoid) for all available samples at baseline. This bar plot shows the composition and variation of cellular components, including unassigned cells, across all patients. The cell types were identified using a semi-automated approach with the software Astrolabe. B, Heatmap map showing differentially abundant cell type changes over time. The rows are shown as relative abundance or scaled ( z -score) allowing comparison across samples for each cell type simultaneously. C–F, Boxplots and line plots colored based on treatment showing the dynamics for the differentially abundant cell types. G, Boxplots showing the differentially abundant cells between treatments at baseline. H, Comparison of cell abundances for different treatments after the start of treatment.

Year:

2025

Association of plasma cytokines with clinical benefit. A , C , and E, PFS survival analysis shows the Kaplan–Meier curves for VEGFR2, CXCL9, and MUC16, respectively. Statistics using log-rank test and Cox proportional hazard models are shown. Higher than median VEGFR2 levels were associated with slower progression whereas higher than median levels of CXCL9 and MUC16 were associated with faster progression. B , D , and F, Forest plots for VEGFR2, CXCL9, and MUC16, respectively. Here, we show the multivariate statistics for each of these proteins including sex, age, treatment type, and cancer stage (Ann Arbor stage). These figures verify the directionality of the KM curves shown and show that these three proteins are independent of these clinically relevant covariates. G, Shows the receiver operating characteristic (ROC) curves for the prediction of PFS using VEGFR2, MUC16, CXCL9, PDL1, and clinical variables. Ordered from most relevant to least relevant model, reflected on the AUC values. H, Univariate PFS Cox modeling of Olink analytes. I, Univariate OS Cox modeling of Olink analytes. Both I and H , show on the x -axis the HR and the y -axis shows the −log 10 ( P values) based on the log-rank test.

Year:

2025

Protein dynamics in HL during checkpoint blockade treatment. A, Overview of the clinical trial E4412 experimental design. Three treatment arms included: (i) BV + ipilimumab (I), (ii) BV + nivolumab (N), and (iii) BV + I + N, with participant number ( n ) indicated. B, Regression modeling strategy using mixed effect models applied to analyze independently four different assay methodologies. Each assay was modeled considering relevant clinical variables and adjusted for multiple testing using FDR correction. C, Summary heatmap showing the log 2 -fold change (log 2 FC) between time points and treatments. The changes with a positive log 2 FC over time in color blue are associated with a decrease over time and red with an increase over time. The −log 10 ( P value) is represented by the size of the circles, indicating statistical significance as the circles increase. D, Line and boxplot figures showing the changes in expression for markers increased posttreatment such as PDCD1, GMZA, PTN, CAIX, IL18, CD28, and markers decreased posttreatment such as CCL17, ANGPT2, IL13, and CXCL13. E, Summary heatmap of differential expression associated with response. The changes with a positive log 2 FC in color blue are associated with a lower expression in nonresponders and red with higher expression in nonresponders. F, Line and boxplot examples of significant ( P

Year:

2025

To investigate the cellular and molecular mechanisms associated with targeting CD30-expressing Hodgkin lymphoma (HL) and immune checkpoint modulation induced by combination therapies of CTLA4 and PD1, we leveraged Phase 1/2 multicenter open-label trial NCT01896999 that enrolled patients with refractory or relapsed HL (R/R HL). Using peripheral blood, we assessed soluble proteins, cell composition, T-cell clonality, and tumor antigen-specific antibodies in 54 patients enrolled in the phase 1 component of the trial. NCT01896999 reported high (>75%) overall objective response rates with brentuximab vedotin (BV) in combination with ipilimumab (I) and/or nivolumab (N) in patients with R/R HL. We observed a durable increase in soluble PD1 and plasmacytoid dendritic cells as well as decreases in plasma CCL17, ANGPT2, MMP12, IL13, and CXCL13 in N-containing regimens (BV + N and BV + I + N) compared with BV + I (P < 0.05). Nonresponders and patients with short progression-free survival showed elevated CXCL9, CXCL13, CD5, CCL17, adenosine–deaminase, and MUC16 at baseline or after one treatment cycle and a higher prevalence of NY-ESO-1-specific autoantibodies (P < 0.05). The results suggest a circulating tumor-immune-derived signature of BV ± I ± N treatment resistance that may be useful for patient stratification in combination checkpoint therapy. Significance: Identification of multi-omic immune markers from peripheral blood may help elucidate resistance mechanisms to checkpoint inhibitor and antibody–drug conjugate combinations with potential implications for treatment decisions in relapsed HL.

Year:

2024

Supplemental Figure 3. Graphical abstract. Top boxes show a simplified trial design including 3 treatments composed by the combination of BV with I, N and I+N. We investigated the differences between responders and non-responders using standardized assays through the CIMAC’s network (ELISA, Olink, CYTOF and TCRseq). Bottom boxes summarize the main findings associated with specific treatments and treatment associated response or resistance.

Year:

2024

Supplemental Figure 3. Graphical abstract. Top boxes show a simplified trial design including 3 treatments composed by the combination of BV with I, N and I+N. We investigated the differences between responders and non-responders using standardized assays through the CIMAC’s network (ELISA, Olink, CYTOF and TCRseq). Bottom boxes summarize the main findings associated with specific treatments and treatment associated response or resistance.

Year:

2024

Supplemental Figure 2. Cellular marker dynamics in Hodgkin lymphoma during checkpoint blockade treatment. A. Heatmap showing markers and cell types identified through CyTOF (cytometry using time of flight) that significantly change over time. The color indicates the standardized Log2FC in protein expression (Z-Score), and the size of the circles indicate the percent of cells expressing the marker. A dendrogram of the markers sorted hierarchically is shown on the right side. B. Line plots highlight the temporal changes for each of the markers shown in A. The color separates the values per treatment. C. Heatmap showing markers and cell types significantly associated with R (Responder) and NR (Not responder). D. Regression lines for examples of markers and cell types shown in C, separating response (R) and non-response (NR).

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (13)

Jianjun Zhang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Rossana Lazcano

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Franziska Michor

Professor of Computational Biology

Dana-Farber Cancer Institute

UNITED STATES
View details

Edwin Roger Parra

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jiexin Zhang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mary Redman

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Lyudmila Bazhenova

University of California

UNITED STATES
View details

Cara Haymaker

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Gheath Alatrash

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Karen Kelly

Professor of Medicine

University of California Davis Comprehensive Cancer Center

UNITED STATES
View details

Catherine Diefenbach

Assistant Professor of Medicine

NYU School of Medicine

UNITED STATES
View details

Edgar Ernesto Gonzalez Kozlova

Assistant Professor

-

UNITED STATES
View details